Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes

Jun 24, 2020Pharmacological research

Dulaglutide's effectiveness and factors linked to response in type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

A significant reduction in glycated hemoglobin (HbA1c) of -1 ± 0.8 % was observed at 6 months in patients treated with dulaglutide.

The percentage of subjects achieving HbA1c≤7.0 % increased from 7.2 % at baseline to 52.7 % at 6 months and 55.8 % at 12 months.
Predictors for achieving HbA1c≤7.0 % include lower baseline HbA1c levels and a shorter duration of diabetes.
Reductions in HbA1c were associated with decreases in body mass index (BMI), waist circumference, fasting plasma glucose, and blood pressure.
Age and sex did not significantly affect any clinical or laboratory outcomes.
Dulaglutide showed a greater effect on HbA1c in patients transitioning from dipeptidyl peptidase-IV inhibitors compared to those shifting from other GLP-1 receptor agonists.

AI simplified

Aim of this retrospective multicenter observational study was to evaluate the efficacy and safety of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) dulaglutide in a type-2 diabetic real-world population and to determine the factors predicting the response in terms of glycated haemoglobin (HbA1c) and other relevant clinical outcomes. Data for efficacy outcomes, adverse events and drug discontinuation were collected from records of patients with type-2 diabetes treated with once-a-week 1.5 mg of dulaglutide for 12 months in routine clinical practice. Initial analysis included 782 patients and 626 had complete follow-up at 6- and 12-months. There was a significant reduction of HbA1c at 6 months (-1 ± 0.8 %, p < 0.0001), which remained stable at 12-months follow-up (-1 ± 0.9 %, p < 0.0001). The percentage of subjects with HbA1c≤7.0 % increased significantly from 7.2 % at baseline to 52.7 % at 6 months to 55.8 % at 12 months. Predictors of the achievement of HbA1c≤7.0 % were low baseline HbA1c and short duration of diabetes. The reduction of HbA1c was associated with reductions of BMI, waist circumference, fasting plasma glucose and blood pressures. Neither sex nor age had significant effects on any clinical or laboratory outcome. The effects of dulaglutide on HbA1c, BMI and SBP tended to be greater in patients who shifted from dipeptidyl peptidase-IV inhibitors (-0.8 ± 0.8 %) than other GLP-1 RA, even if an improvement of HbA1c reduction (-0.5 %) was also seen in those shifting from other GLP-1 RA. This study confirms that addition of dulaglutide 1.5 mg once a week in real word settings has beneficial effects on both clinical and laboratory outcomes in patients with uncontrolled type-2 diabetes. Dulaglutide has a greater effect on HbA1c in patients with higher baseline values and helps achieve a target HbA1c≤7.0 %, more consistently in patients with lower baseline HbA1c and shorter diabetes duration.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief